Ulf Hannelius

Company: Diamyd

Job title: President & Chief Executive Officer

Seminars:

Decoding the Future: Leveraging Biomarkers in Antigen-Specific Immunotherapy for Type 1 Diabetes 12:15 pm

Discussing immunological and genetic findings from clinical trials evaluating the antigenspecific immunotherapy Diamyd (rhGAD65/alum) Highlighting the significance of HLA testing, exploring HLA haplotype frequencies and their relevance for personalized immunotherapy approaches and patient selection Designing the Phase 3 trial DIAGNODE-3 from a biomarker perspective, including the collection of data for future potential personalization of the investigational therapyRead more

day: Conference Day One